Effectiveness of NextDose for Warfarin Dose Individualization

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objectives:

To understand whether the implementation of warfarin dose management using NextDose (nextdose.org) at The First Affiliated Hospital of Soochow University (Suzhou, China) improves the quality of anticoagulation therapy.

Endpoint Primary

1\. Percentage of time within the acceptable INR range estimated using linear interpolation during the 28 days after initiation of warfarin.

Secondary 2.1 Percentage of Time Measures 2.2 Time to Stable Dose 2.3 Safety Outcomes 2.4 Acceptability of NextDose Recommendations Exploratory 3.1 Percentage of Time Measures 3.2 Time to Stable Dose 3.3 Safety Outcomes 3.4 Acceptability of NextDose Recommendations 3.5 Model Evaluation 3.6 INR Variability

Population:

240 participants of any sex between the age of 18 and 80 years. Patients requiring treatment with warfarin following cardiac surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prospective Cohort Study on Warfarin Personalized Medication

NCT06428110

Warfarin Sodium Causing Adverse Effects in Therapeutic Use

COMPLETED

Study of Genetic Factors Other Than CYP2C9 and VKORC1 That Influence Warfarin Dose Requirements in a South-east Asian Population

NCT01050920

Cancer

UNKNOWN

Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose

NCT00700895

Indications for Warfarin Therapy

UNKNOWN PHASE3

Assessment of 2012 Bioequivalence Standards for Warfarin

NCT02574754

Healthy

COMPLETED PHASE1

Prospective Trial of a Validated Algorithm for Warfarin Dosing

NCT02705976

Anticoagulation

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives:

To understand whether the implementation of warfarin dose management using NextDose (nextdose.org) at The First Affiliated Hospital of Soochow University (Suzhou, China) improves the quality of anticoagulation therapy.

Endpoint Primary

1. Percentage of time within the acceptable INR range estimated using linear interpolation during the 28 days after initiation of warfarin.

Secondary 2.1 Percentage of Time Measures
1. Percentage of time within the acceptable INR Range estimated using linear interpolation during the 90 days after initiation of warfarin.
2. Percentage of time spent above and below the acceptable INR range at day 28, and 90 after initiation of warfarin estimated by linear interpolation.

2.2 Time to Stable Dose a. Number of days to achievement of stable dose (defined as 3 consecutive INR measurements within acceptable range for the same mean daily dose).

2.3 Safety Outcomes a. Number of participants who experience at least one of the following safety events: major bleeding within 30 days, INR of 4 or greater within 30 days, death within 30 days, and symptomatic or asymptomatic VTE confirmed by objective testing within 60 days of surgery.

2.4 Acceptability of NextDose Recommendations
1. Percentage of prescribed doses within 0.625 mg of the NextDose proposed dose.
2. Mean difference between the prescribed dose and the NextDose proposed dose. Exploratory 3.1 Percentage of Time Measures

a. The percentage of time spent within, above and below the acceptable INR range estimated by numerical integration with the Bayesian parameter estimates of the PKPD model at day 28 and at day 90 after initiation of warfarin.

3.2 Time to Stable Dose a) Days to first INR measurement within the acceptable range. b) Days to second consecutive INR measurement within the acceptable range. c) Number of dose adjustments to achievement of stable dose (3 consecutive INR measurements within acceptable range for the same mean daily dose).

d) Total number of dose adjustments at day 90. e) Total number of INR measurements at day 90. 3.3 Safety Outcomes

a) Incidence of minor and major bleeding events. b) Incidence of thromboembolic events. c) 30 day all-cause mortality. d) 90 day all-cause mortality. e) 90 day cardiovascular mortality. f) Number of warfarin doses withheld due to high INR (as determined by the treating clinician).

3.4 Acceptability of NextDose Recommendations a) Percentage of prescribed doses within 20% of the NextDose proposed dose. 3.5 Model Evaluation

a) Predictive performance of the model for patients with steady-state warfarin doses below 2 or above 7 mg/day.

3.6 INR Variability

a) INR variability as described by Lind et al. (the standard deviation of transformed INR values).

Population:

240 participants of any sex between the age of 18 and 80 years. Patients requiring treatment with warfarin following cardiac surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombosis Embolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Current warfarin dose individualization methods tend to be empirical, rather than based upon pharmacological and statistical principles. A theory-based model of warfarin pharmacokinetics and pharmacodynamics (PKPD) has been developed for dose individualization when used in conjunction with a Bayesian forecasting tool (NextDose).

This study compares standard of care clinician judgement for warfarin management with the use of a web-based dosing tool (NextDose). Computer-assisted anticoagulant dosing has been shown to be helpful using empirical models. This study will evaluate a theory-based model which has shown superior performance over empirical models in predicting clinical doses of warfarin. The study is also guided by quality and service improvement principles.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

All patients who are screened for enrolment will be allocated an enrolment number. The recruiting clinician will record into a logbook the details of all patients screened for enrolment, including the reason for exclusion from trial entry.

A randomization sequence using block randomization with random block sizes of 4, 6 and 8 (to maintain equal sample size in each arm) will be created by researchers using PASS. Assignments will be enclosed in sequentially numbered, opaque, sealed envelopes.

Participants who provide written informed consent and are enrolled will be allocated to study arm by the study pharmacists. The pharmacist will be responsible for opening envelopes sequentially, writing the participant enrollment number on the envelope prior to opening, and recording the envelope number and study arm allocation in the CRF. On conclusion of the data collection phase, the (actual) study allocation status of the participants will be compared to the randomization sequence.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Arm

NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.

Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose.

Group Type EXPERIMENTAL

NextDose (nextdose.org)

Intervention Type DEVICE

NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.

Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose.

Control Arm

Usual standard of care. Clinical experience of the treating physician taking into account the covariates, dosing and INR history of each patient, to determine the initial, and subsequent maintenance doses.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NextDose (nextdose.org)

NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.

Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Scheduled to undergo cardiac surgery with planned warfarin anticoagulation for at least three months.
* Age ≥ 18 and \< 80 years.
* Written informed consent has been obtained.

Exclusion Criteria

* Allergy to warfarin tablet or excipients.
* Enrollment or planned enrollment in other research that would conflict with full participation in the study or confound the observation or interpretation of the study findings.
* Patients who in the opinion of the recruiting clinician are:

* unwilling or unable to comply with the protocol requirements and/or,
* considered unreliable concerning the requirements for follow-up during the study and/or, compliance with drug administration.
* Patient with life expectancy less than the expected duration of the trial due to concomitant disease.
* Contraindication to warfarin therapy. The following are examples but not an exhaustive list:

* Pregnancy.
* Cerebral infarction or cerebral haemorrhage (from patients' medical record) within the 3 months prior to heart valve replacement
* Severe heart failure (New York Heart Function Class IV)
* Severe renal failure (CLcr (Cockcroft-Gault) ≤20mL / min)
* Severe liver failure (Child-Pugh≥10)
* Abnormal liver function (elevated transaminase more than three times the upper limit of the local hospital clinical laboratory).

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Miao Liyan

vice-president

Responsibility Role PRINCIPAL_INVESTIGATOR